Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)

Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.

Also Known As:

Networked: 4313 relevant articles (562 outcomes, 985 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Akl, Elie A: 24 articles (08/2015 - 01/2008)
2.	Mousa, Shaker A: 23 articles (03/2015 - 01/2002)
3.	Büller, H R: 22 articles (09/2015 - 01/2000)
4.	Prandoni, Paolo: 20 articles (11/2015 - 05/2004)
5.	Agnelli, Giancarlo: 18 articles (03/2015 - 07/2002)
6.	Warkentin, Theodore E: 18 articles (02/2015 - 06/2002)
7.	Büller, Harry R: 17 articles (11/2015 - 03/2002)
8.	Lee, Agnes Y Y: 17 articles (08/2015 - 06/2003)
9.	Barba, Maddalena: 17 articles (01/2014 - 01/2008)
10.	Di Nisio, Marcello: 16 articles (11/2015 - 05/2004)

Related Diseases

1.	Venous Thrombosis (Deep-Vein Thrombosis) 04/01/1999 - "The results have been very encouraging and suggest that the use of subcutaneous LMWH in highly selected, uncomplicated venous thrombosis patients is as safe and effective as intravenous UFH, and that most patients can be treated as outpatient or be discharged early. " 01/01/1997 - "This study confirmed that a very low dose of 1750 anti-Xa IU daily of this new LMWH is as effective as 10,000 IU of UFH for preventing postoperative deep vein thrombosis. " 05/15/1997 - "In recent years low molecular weight heparins (LMWH) have proven to be effective and safe both for prophylactic (3) and therapeutic treatment (4) of deep vein thrombosis (DVT). " 01/01/1994 - "[Comparative study of the efficacy of a low dose of antivitamin K and a preventive dose of low molecular weight heparin in the prevention of relapses of deep venous thrombosis after curative treatment in the aged subject]." 02/01/1997 - "Evidence from randomized clinical trials demonstrates that LMWH is effective in the prevention of deep vein thrombosis (DVT) in high-risk orthopedic patients. "
2.	Venous Thromboembolism 09/01/1998 - "In conclusion, low-molecular-weight heparin is highly effective in preventing post-operative venous thromboembolism." 12/01/2001 - "This article reviews the developments that have occurred in the treatment of venous thromboembolism during the last decade, with emphasis on the establishment of low molecular weight heparin as a therapeutic agent of proven efficacy and examines the evidence that supports the movement from inpatient to outpatient hospital management of venous thromboembolism." 12/01/1996 - "Low molecular weight heparin have markedly improved the efficacy of prevention and treatment of venous thromboembolism." 10/01/2008 - "The present study is the largest study to have examined the clinical efficacy of once daily LMWH for use in pregnant women at high risk of venous thromboembolism. " 01/01/2002 - "Analysis of pooled data for category I studies showed a non-significant reduction in the risk of recurrent venous thromboembolism favoring low-molecular-weight heparin treatment (OR 0.75; 95% CI [0.40, 1.39]). "
3.	Neoplasms (Cancer) 08/01/2010 - "Low-molecular-weight heparin remains the best treatment option for initial and long term treatment of VTE in cancer patients." 10/01/2008 - "The current results indicated that LMWH most likely is superior to UFH in reducing mortality in the initial treatment of VTE for patients with cancer. " 01/01/2015 - "Experimental and preclinical studies further suggest that LMWH may be beneficial in cancer therapy, but this innovative concept has not yet been proven beyond doubt in rigorously designed clinical trials. " 04/01/2012 - "The advantage of LMWH in cancer patients consists predominantly in a significantly better protection against DVT episodes, whereas the advantage of LMWH in non-cancer patients is mainly owed to better protection against minor bleedings. " 01/01/2009 - "Whether the long-term dose of LMWH can be reduced remains unresolved: Intermediate dose LMWH has been used effectively in cancer patients, who - like pregnant women - continue to have a high pro-thrombotic burden after the initial phase. "
4.	Hemorrhage 08/01/2004 - "In very high-risk patients, a higher dose of LMWH may offer increased efficacy without increasing bleeding risk. " 10/01/2003 - "However the optimal LMWH regimen, offering the greatest efficacy with an acceptable risk of bleeding, has not been clearly established with regard to dose and timing of treatment initiation. " 01/01/2012 - "Analysis of pooled data for category I trials (those with a high methodological quality) showed a non-significant reduction in the odds of recurrent VTE favouring LMWH treatment (OR 0.80, 95% CI 0.54 to 1.18).For all trials combined, the difference in bleeding significantly favoured treatment with LMWH (OR 0.50, 95% CI 0.31 to 0.79). " 09/01/2003 - "When all studies were combined, a statistically non-significant reduction in the risk of VTE (OR 0.66; 95% confidence interval [CI] 0.41, 1.07) and in the risk of major bleeding (OR 0.45; 95% CI 0.18, 1.11) in favor of LMWH treatment was found. " 11/01/1991 - "The conclusions of all these trials are: LMWH is relatively simple to use and, compared with UFH, has a more stable anticoagulant effect due to its pharmacokinetic properties; the therapeutic efficacy is as good as, if not better, than that of UFH; the risk of bleeding remains, therefore, the specified dosages should be respected and treatment should be monitored by anti-Xa activity when indicated; the decreased interaction with platelet function should not mask the risk of thrombocytopoenia.(ABSTRACT TRUNCATED AT 400 WORDS)"
5.	Thrombosis (Thrombus) 06/01/2002 - "Successful management of acute portal vein thrombosis by low molecular weight heparin and oral anticoagulation." 07/30/1994 - "A significant reduction in the incidence of thrombus extension (common odds ratio 0.51, 95% confidence interval 0.32 to 0.83; P = 0.006) in favour of low molecular weight heparin was observed. " 09/01/2001 - "For other patients at higher risk of thrombosis, "bridging therapy" with outpatient low molecular weight heparin is safe and effective. " 05/08/1999 - "Results point towards equivalent or greater efficacy, with reduction in thrombosis size, and safety of low molecular weight heparin. " 01/01/1988 - "In the doses administered, LMWH and UH seem effective in the prevention of thrombosis. "

Related Drugs and Biologics

1.	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
2.	Heparin (Liquaemin)
3.	Enoxaparin (Lovenox)
4.	Dalteparin (Dalteparin Sodium)
5.	Warfarin (Coumadin)
6.	Aspirin (Acetylsalicylic Acid)
7.	fondaparinux (Arixtra)
8.	Vitamin K
9.	tinzaparin (Innohep)
10.	Anticoagulants

Related Therapies and Procedures

1.	Renal Dialysis (Hemodialysis)
2.	Arthroplasty
3.	Hip Replacement Arthroplasty (Total Hip Replacement)
4.	Compression Stockings
5.	Vitrectomy